Literature DB >> 16737665

Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects.

Roman Huber1, Matthias Rostock, Roland Goedl, Rainer Lüdtke, Konrad Urech, Reinhild Klein.   

Abstract

The subcutaneous application of lectin-rich mistletoe preparations such as Iscador Quercus (IQ; Weleda Company, Schwäbisch Gmünd, Germany) results in a peripheral eosinophilia. Our goal was to investigate whether this effect is related to mistletoe lectin (ML) and whether it is caused by a response of the specific immune system. In a double-blinded study, 43 volunteers were randomized to one of four treatment groups: (1) IQ, (2) ML that was derived from IQ, (3) IQ that was depleted of ML, and (4) placebo. The respective preparations were applied subcutaneously twice per week for 8 weeks, in increasing doses. Weekly the differential blood count was analyzed. Every 4 weeks interferon-gamma, interleukin-5 (IL-5), and granulocyte-macrophage colony stimulating factor (GM-CSF) were determined in cultures from peripheral mononuclear cells after stimulation with IQ. IQ and ML resulted in significant eosinophilia compared with placebo and ML-depleted IQ. Furthermore, the leukocyte and granulocyte counts were increased in the IQ and ML groups compared with placebo. GM-CSF, interferon-gamma, and IL-5 increased after ex vivo in vitro stimulation with IQ in the IQ and ML groups, and were significantly different from placebo in the IQ group but not in the ML group. Eosinophilia during therapy with mistletoe preparations is due to its content of ML. This effect might be related to a stimulation of IL-5 and/or GM-CSF, which was demonstrated ex vivo in vitro. ML resulted in a temporary increase of the granulocyte count, which is probably related to an acute-phase reaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737665

Source DB:  PubMed          Journal:  J Soc Integr Oncol        ISSN: 1715-894X


  5 in total

1.  Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model.

Authors:  Carmen Steinborn; Amy Marisa Klemd; Ann-Sophie Sanchez-Campillo; Sophie Rieger; Marieke Scheffen; Barbara Sauer; Manuel Garcia-Käufer; Konrad Urech; Marie Follo; Annekathrin Ücker; Gunver Sophia Kienle; Roman Huber; Carsten Gründemann
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

2.  Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.

Authors:  Peiying Yang; Yan Jiang; Yong Pan; Xiaoping Ding; Patrea Rhea; Jibin Ding; David H Hawke; Dean Felsher; Goutham Narla; Zhimin Lu; Richard T Lee
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

3.  Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant Momordica charantia Induces Inflammatory Responses by Activating the NF-kappaB and JNK Pathways.

Authors:  Ying-Jie Chen; Jia-Qian Zhu; Xiu-Qiong Fu; Tao Su; Ting Li; Hui Guo; Pei-Li Zhu; Sally Kin-Wah Lee; Hua Yu; Anfernee Kai-Wing Tse; Zhi-Ling Yu
Journal:  Toxins (Basel)       Date:  2019-11-26       Impact factor: 4.546

4.  Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Authors:  Renatus Ziegler
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

5.  Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice.

Authors:  Sonja Schötterl; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-27       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.